Cargando…
CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
BACKGROUND: Prostate cancer progresses slowly when present in low risk forms but can be lethal when it progresses to metastatic disease. A non-invasive test that can detect significant prostate cancer is needed to guide patient management. METHODS: Capillary electrophoresis/mass spectrometry has bee...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738044/ https://www.ncbi.nlm.nih.gov/pubmed/31092909 http://dx.doi.org/10.1038/s41416-019-0472-z |
_version_ | 1783450770817941504 |
---|---|
author | Frantzi, Maria Gomez Gomez, Enrique Blanca Pedregosa, Ana Valero Rosa, José Latosinska, Agnieszka Culig, Zoran Merseburger, Axel S. Luque, Raul M. Requena Tapia, María José Mischak, Harald Carrasco Valiente, Julia |
author_facet | Frantzi, Maria Gomez Gomez, Enrique Blanca Pedregosa, Ana Valero Rosa, José Latosinska, Agnieszka Culig, Zoran Merseburger, Axel S. Luque, Raul M. Requena Tapia, María José Mischak, Harald Carrasco Valiente, Julia |
author_sort | Frantzi, Maria |
collection | PubMed |
description | BACKGROUND: Prostate cancer progresses slowly when present in low risk forms but can be lethal when it progresses to metastatic disease. A non-invasive test that can detect significant prostate cancer is needed to guide patient management. METHODS: Capillary electrophoresis/mass spectrometry has been employed to identify urinary peptides that may accurately detect significant prostate cancer. Urine samples from 823 patients with PSA (<15 ng/ml) were collected prior to biopsy. A case–control comparison was performed in a training set of 543 patients (n(Sig) = 98; n(non-Sig) = 445) and a validation set of 280 patients (n(Sig) = 48, n(non-Sig) = 232). Totally, 19 significant peptides were subsequently combined by a support vector machine algorithm. RESULTS: Independent validation of the 19-biomarker model in 280 patients resulted in a 90% sensitivity and 59% specificity, with an AUC of 0.81, outperforming PSA (AUC = 0.58) and the ERSPC-3/4 risk calculator (AUC = 0.69) in the validation set. CONCLUSIONS: This multi-parametric model holds promise to improve the current diagnosis of significant prostate cancer. This test as a guide to biopsy could help to decrease the number of biopsies and guide intervention. Nevertheless, further prospective validation in an external clinical cohort is required to assess the exact performance characteristics. |
format | Online Article Text |
id | pubmed-6738044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67380442020-05-16 CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer Frantzi, Maria Gomez Gomez, Enrique Blanca Pedregosa, Ana Valero Rosa, José Latosinska, Agnieszka Culig, Zoran Merseburger, Axel S. Luque, Raul M. Requena Tapia, María José Mischak, Harald Carrasco Valiente, Julia Br J Cancer Article BACKGROUND: Prostate cancer progresses slowly when present in low risk forms but can be lethal when it progresses to metastatic disease. A non-invasive test that can detect significant prostate cancer is needed to guide patient management. METHODS: Capillary electrophoresis/mass spectrometry has been employed to identify urinary peptides that may accurately detect significant prostate cancer. Urine samples from 823 patients with PSA (<15 ng/ml) were collected prior to biopsy. A case–control comparison was performed in a training set of 543 patients (n(Sig) = 98; n(non-Sig) = 445) and a validation set of 280 patients (n(Sig) = 48, n(non-Sig) = 232). Totally, 19 significant peptides were subsequently combined by a support vector machine algorithm. RESULTS: Independent validation of the 19-biomarker model in 280 patients resulted in a 90% sensitivity and 59% specificity, with an AUC of 0.81, outperforming PSA (AUC = 0.58) and the ERSPC-3/4 risk calculator (AUC = 0.69) in the validation set. CONCLUSIONS: This multi-parametric model holds promise to improve the current diagnosis of significant prostate cancer. This test as a guide to biopsy could help to decrease the number of biopsies and guide intervention. Nevertheless, further prospective validation in an external clinical cohort is required to assess the exact performance characteristics. Nature Publishing Group UK 2019-05-16 2019-06-11 /pmc/articles/PMC6738044/ /pubmed/31092909 http://dx.doi.org/10.1038/s41416-019-0472-z Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Article Frantzi, Maria Gomez Gomez, Enrique Blanca Pedregosa, Ana Valero Rosa, José Latosinska, Agnieszka Culig, Zoran Merseburger, Axel S. Luque, Raul M. Requena Tapia, María José Mischak, Harald Carrasco Valiente, Julia CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer |
title | CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer |
title_full | CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer |
title_fullStr | CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer |
title_full_unstemmed | CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer |
title_short | CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer |
title_sort | ce–ms-based urinary biomarkers to distinguish non-significant from significant prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738044/ https://www.ncbi.nlm.nih.gov/pubmed/31092909 http://dx.doi.org/10.1038/s41416-019-0472-z |
work_keys_str_mv | AT frantzimaria cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer AT gomezgomezenrique cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer AT blancapedregosaana cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer AT valerorosajose cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer AT latosinskaagnieszka cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer AT culigzoran cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer AT merseburgeraxels cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer AT luqueraulm cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer AT requenatapiamariajose cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer AT mischakharald cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer AT carrascovalientejulia cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer |